Table 1.
Patient characteristics
| Patient no. | Age (yr) | Sex | Transplant | PLA2R/ THSD7A on Biopsy | Serum Anti-PLA2R (RU/ml) |
UPCR (g/g) | Serum albumin (g/dl) | Serum creatinine (mg/dl) | Previous treatment |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | F | No | Negative | Negative | 14.38 | 2.9 | 1.1 | Rituximab and ARB |
| 2 | 66 | M | No | Negative | 633 | 11.3 | 1.7 | 2.1 | Rituximab and ARB |
| 3 | 41 | M | No | PLA2R+ | 39 | 10.73 | 2.7 | 0.9 | Tacrolimus, prednisone, and ARB |
| 4 | 68 | M | No | PLA2R+ | 261 | 7.8 | 2.1 | 1.3 | Rituximab and ARB |
| 5 | 49 | M | No | Negative | 4.5 | 3.9 | 0.9 | Cyclophosphamide, prednisone, and rituximab | |
| 6 | 24 | F | No | Negative | 3.65 | 2.5 | 1.1 | Cyclophosphamide, mycophenolate, prednisone, and rituximab | |
| 7 | 76 | F | Yes | PLA2R+, THSD7A+ | 79 | 5.8 | 2.8 | 1.4 | Tacrolimus, prednisone, and ARB |
| 8 | 67 | M | Yes | THSD7A+ | 57 | 8.49 | 2.8 | 1.5 | Rituximab, ARB, tacrolimus, and prednisone mycophenolate |
| 9 | 69 | F | Yes | Negative | Negative | 4.7 | 3.6 | 2.2 | Rituximab, ARB, synthetic ACTH, tacrolimus, prednisone, and mycophenolate |
| 10 | 50 | M | Yes | PLA2R+ | Negative | 4.5 | 3.6 | 1.5 | Tacrolimus, prednisone, mycophenolate, and ARB |
ACTH, adrenocorticotrophic hormone; ARB, angiotensin II receptor blocker; PLA2R, phospholipase A2 receptor; THSD7A, thrombospondin type 1 domain-containing 7A; UPCR, urine protein-to-creatinine ratio.